Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine.
about
Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal CancerTrial Watch: Peptide-based anticancer vaccines.PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancerPersonalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
P2860
Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Juzentaihoto Failed to Augment ...... Personalized Peptide Vaccine.
@en
type
label
Juzentaihoto Failed to Augment ...... Personalized Peptide Vaccine.
@en
prefLabel
Juzentaihoto Failed to Augment ...... Personalized Peptide Vaccine.
@en
P2093
P2860
P356
P1476
Juzentaihoto Failed to Augment ...... r Personalized Peptide Vaccine
@en
P2093
Akira Yamada
Kyogo Itoh
Munehiro Yoshitomi
Nobukazu Komatsu
Satoko Matsueda
Shigeru Yutani
Takahisa Shirahama
P2860
P304
P356
10.1155/2013/981717
P577
2013-06-10T00:00:00Z